Akero Therapeutics, Inc.
AKRO
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 743.08M | 717.25M | 760.19M | 903.67M | 550.01M |
Total Receivables | -- | -- | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 27.30M | 29.64M | 15.82M | 7.62M | 9.95M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 770.38M | 746.89M | 776.01M | 911.28M | 559.96M |
|
|||||
Total Current Assets | 770.38M | 746.89M | 776.01M | 911.28M | 559.96M |
Net Property, Plant & Equipment | 755.00K | 835.00K | 900.00K | 963.00K | 1.03M |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | -- | -- | -- | -- | -- |
Total Assets | 825.89M | 817.55M | 865.04M | 912.24M | 580.27M |
|
|||||
Total Accounts Payable | 9.03M | 25.22M | 14.57M | 13.78M | 7.04M |
Total Accrued Expenses | 30.10M | 17.44M | 15.98M | 15.84M | 11.57M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 291.00K | 283.00K | 275.00K | 267.00K | 522.00K |
Total Finance Division Other Current Liabilities | 340.00K | 348.00K | 354.00K | 373.00K | -- |
Total Other Current Liabilities | 340.00K | 348.00K | 354.00K | 373.00K | -- |
Total Current Liabilities | 39.75M | 43.29M | 31.17M | 30.26M | 19.13M |
|
|||||
Total Current Liabilities | 39.75M | 43.29M | 31.17M | 30.26M | 19.13M |
Long-Term Debt | 35.30M | 35.12M | 34.96M | 34.80M | 24.96M |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 529.00K | 605.00K | 679.00K | 750.00K | 819.00K |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 194.00K | 203.00K | 164.00K | 178.00K | 54.00K |
Total Liabilities | 75.77M | 79.22M | 66.98M | 65.99M | 44.97M |
|
|||||
Common Stock & APIC | 1.58B | 1.49B | 1.48B | 1.47B | 1.11B |
Retained Earnings | -826.16M | -756.13M | -683.43M | -627.44M | -574.10M |
Treasury Stock & Other | 948.00K | 2.10M | -261.00K | -79.00K | 270.00K |
Total Common Equity | 750.11M | 738.33M | 798.07M | 846.25M | 535.31M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 750.11M | 738.33M | 798.07M | 846.25M | 535.31M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 750.11M | 738.33M | 798.07M | 846.25M | 535.31M |
|